Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation

Abstract

Estimates of the economic burden posed by AF are critical in light of the increasing importance of AF as a public health problem.

Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients

“…25 The frequency by which different statin preparations and ezetimibe were used was obtained from the United Kingdom General Practice Research Database 26. Event costs and lifetime health care costs associated with vascular events were derived from observational studies in The Netherlands and from Dutch nation‐wide registries 27, 28, 29, 30, 31. Mean costs for a revascularization procedure were estimated as the weighted sum of costs for a PCI and a CABG 17.…”

Impact of Medical Treatment on Long-Term Results after Surgical Ablation of Atrial Fibrillation in Cardiac Surgical Patients

“…4) AF currently represents a major economic burden for society in light of the aging population. [5][6][7] The Maze procedure provides excellent results for surgical treatment of AF. 8) This surgical approach was designed to block multiple macroreentrant circuits that were the putative cause of AF.…”

Atrial fibrillation - European and Swiss perspectives. Reflections on epidemiology, costs and treatment options.

“…In several reports, AF was associated with average healthcare costs from 971 euros per patient per year (Poland) up to 3027 euros per patient per year (France, Italy) [11]. Total costs for treating AF were 655 million euros in the UK in year 2000 [10] and 690 million eu ros in Germany in 2006.…”

“…Total costs for treating AF were 655 million euros in the UK in year 2000 [10] and 690 million eu ros in Germany in 2006. The Euro Heart Survey which included 5333 patients in 35 countries identified hospi talisations and interventional procedures in patients with AF as main determinants of costs accounting for >70% of total costs [11]. Except from direct healthcare costs, indirect costs also rise as a consequence of early retirement or sick leaves and are assumed to be from 39 euros average per patient per year (Poland) to more than 3000 euros average per patient per year in Italy or Germany [11] adding an additional 20% to the total costs of treatment [11,12].…”

“…The Euro Heart Survey which included 5333 patients in 35 countries identified hospi talisations and interventional procedures in patients with AF as main determinants of costs accounting for >70% of total costs [11]. Except from direct healthcare costs, indirect costs also rise as a consequence of early retirement or sick leaves and are assumed to be from 39 euros average per patient per year (Poland) to more than 3000 euros average per patient per year in Italy or Germany [11] adding an additional 20% to the total costs of treatment [11,12]. In Switzerland, the DRG derived reimbursement (DRG = diagnosisrelated group) for a patient undergoing pulmonary vein isola tion (PVI) is approximately 25 000 CHF and with >1500 PVIs performed in Switzerland in 2012 this re sults in costs of approximately 40 million CHF per year.…”